Evolocumab
Amgen
[]
full house for the late-breaking results of yellow-iii trial! significant in #tcfa in 80% with use of #pcsk9 inhibition! all the hard work behind the scenes, detailed #oct and #ivus by #acc23 
Interventional Cardiologist, Structrual heart fellow @MountSinaiHeart | 🇦🇺 from Melbourne | PhD @unimelb